Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

81. Individual support of nurses using electronic medicine monitors can improve HIV treatment

Individual support of nurses using electronic medicine monitors can improve HIV treatment Individual support of nurses using electronic medicine monitors can improve HIV treatment Discover Portal Discover Portal Individual support of nurses using electronic medicine monitors can improve HIV treatment Published on 10 October 2017 doi: Use of electronic pill bottles that record when they are opened and follow-up discussion of the printed readouts with nurses improved HIV outcomes. It is thought (...) that patients became more reliable in taking the medication, which can have complicated scheduling. Overall, the HIV virus in the blood and the risk of treatment failure were lower in the group of patients who had access to this intervention compared to regular care. In addition to being more effective, the programme also reduced the estimated lifetime cost and disease burden per patient, considering quality and quantity of life lived. The readouts were used to help focus attention on any patterns

2019 NIHR Dissemination Centre

82. Self-testing kits increase overall HIV testing uptake in men who have sex with men

Self-testing kits increase overall HIV testing uptake in men who have sex with men Self-testing kits increase overall HIV testing uptake in men who have sex with men Discover Portal Discover Portal Self-testing kits increase overall HIV testing uptake in men who have sex with men Published on 6 February 2018 doi: Frequency of HIV testing in men who have sex with men may be increased by one additional test in a six month period when self-testing kits are used. Self-testing kits allow people (...) and support following an HIV diagnosis are of great importance and should include partner notification. Self-testing kits are available in the UK online from and are recommended by Public Health England. Share your views on the research. Why was this study needed? An estimated 89,400 people in the UK are living with HIV according to 2016 figures. The annual rate of new diagnoses is starting to decline, falling from 6,286 in 2015 to 5,164 in 2016. Over half of cases are in men who have sex with men (MSM

2019 NIHR Dissemination Centre

83. Starting antiretroviral therapy immediately after HIV diagnosis reduces transmission of the virus

Starting antiretroviral therapy immediately after HIV diagnosis reduces transmission of the virus Starting antiretroviral therapy immediately after HIV diagnosis reduces transmission of the virus Discover Portal Discover Portal Starting antiretroviral therapy immediately after HIV diagnosis reduces transmission of the virus Published on 16 January 2018 doi: Giving antiretroviral therapy to people newly diagnosed with HIV may be an effective and cost-effective way of reducing new infections (...) . Increased HIV testing in at-risk populations may identify more people for treatment and also reduce infection rates. Using data from a number of sources including NIHR funded projects, researchers developed a computer simulation model. The model looked at the relationship between HIV infections, sexual risk behaviours and antiretroviral therapy over a 30 year period. Introduction of antiretroviral therapies and increased condom use were associated with lower rates of new cases. Most new HIV infections

2019 NIHR Dissemination Centre

84. Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1)

Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet Reference number: 2850 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX (...) /rilpivirine (Juluca ® ? ) 50 mg/25 mg film-coated tablet 1.0 KEY FACTS Assessment details Dolutegravir/rilpivirine (Juluca ® ? ) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA 50 copies/ml but lower than 200 copies/ml in the past 12 months 11 . Previous antiretroviral therapy regimens of two nucleoside reverse transcriptase inhibitors plus a third medicine (a non-nucleoside reverse transcriptase inhibitor, an integrase

2019 All Wales Medicines Strategy Group

85. Methods to estimate the number of people living with undiagnosed HIV

Methods to estimate the number of people living with undiagnosed HIV Methods to estimate the number of people living with undiagnosed HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Methods to estimate the number of people living with undiagnosed HIV Methods to estimate the number of people living with undiagnosed HIV , , , , , , , Questions How do we know how many people are living with undiagnosed HIV infection? What population groups make up people living (...) with undiagnosed HIV infection? Key take-home messages At the end of 2016, the Public Health Agency of Canada estimated that 14% of 63,110 individuals living with HIV in Canada were undiagnosed (1). Different types of data can be used across a variety of methodologies to estimate the undiagnosed proportion of people living with HIV (2, 3). The proportion of individuals living with HIV in Canada who were undiagnosed in 2016 was estimated using a complex statistical method known as “back-calculating”, which

2019 Ontario HIV Treatment Network

86. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

87. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) , Correlation Network, Choices Support Center, Netherlands Jens Lundgren, CHIP/Region H, Denmark Jessika Deblonde, Sciensano, Belgium Jordi Casabona, Center of Epidemiological Studies on HIV and STI in Catalonia (CEEISCAT), Spain Justyna Kowalska, Medical University of Warsaw, Poland Kristi Rüütel, National Institute for Health Development, Estonia Maria Axelsson, Public Health Agency of Sweden, Sweden Maria Elena Tosti, Istituto Superiore di Sanità, Italy Matthew Hickman, University of Bristol, United

2019 European Centre for Disease Prevention and Control - Public Health Guidance

88. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial Full Text available with Trip Pro

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immune reconstitution inflammatory syndrome (IRIS), a paradoxical response to successful ART. Integrase inhibitors lead (...) to significantly more rapid declines in HIV viral load (VL) than all other ART classes. We hypothesised that intensifying standard triple-drug ART with the integrase inhibitor, raltegravir, would reduce HIV VL faster and hence reduce early mortality, although this strategy could also risk more IRIS events.In a 2×2×2 factorial open-label parallel-group trial, treatment-naive adults, adolescents, and children >5 years old infected with HIV, with cluster of differentiation 4 (CD4) <100 cells/mm3, from eight urban

2019 EvidenceUpdates

89. The lived experiences of HIV positive immigrants from HIV endemic sub-Saharan countries: a systematic review

The lived experiences of HIV positive immigrants from HIV endemic sub-Saharan countries: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2019 PROSPERO

90. The impact of task shifting to lay health workers in HIV care continuum on achieving the 90:90:90 targets in sub-Saharan Africa: a systematic review and meta-analysis protocol

The impact of task shifting to lay health workers in HIV care continuum on achieving the 90:90:90 targets in sub-Saharan Africa: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

91. The impact of pharmaceutical care programmes on clinical outcomes, medication adherence and costs in HIV and TB outpatients: a systematic review of pharmacist interventions

The impact of pharmaceutical care programmes on clinical outcomes, medication adherence and costs in HIV and TB outpatients: a systematic review of pharmacist interventions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

92. The global prevalence of depression among people living with HIV/AIDS: a systematic review & meta-analysis

The global prevalence of depression among people living with HIV/AIDS: a systematic review & meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2019 PROSPERO

93. Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis

Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

94. Risk of acute coronary syndrome in people living with HIV on anti-retroviral therapy

Risk of acute coronary syndrome in people living with HIV on anti-retroviral therapy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

95. Systematic review of predictors for HIV pre-exposure prophylaxis uptake in key populations identified in national HIV prevention goals

Systematic review of predictors for HIV pre-exposure prophylaxis uptake in key populations identified in national HIV prevention goals Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

96. HIV positive status disclosure and its predictors among children living with HIV/AIDS in Ethiopia: systematic review and meta-analysis

HIV positive status disclosure and its predictors among children living with HIV/AIDS in Ethiopia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

97. The effectiveness of Internet-based interventions to promote positive behaviours to reduce HIV infections among men who have sex with men in Asia Pacific: a systematic review

The effectiveness of Internet-based interventions to promote positive behaviours to reduce HIV infections among men who have sex with men in Asia Pacific: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

98. Prevalence of metabolic syndrome in people living with HIV on antiretroviral therapy: a systematic review and meta-analysis

Prevalence of metabolic syndrome in people living with HIV on antiretroviral therapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

99. Assessment of the relative effectiveness and safety of vaginal microbicides for preventing sexually transmitted hiv infection: a network meta-analysis

Assessment of the relative effectiveness and safety of vaginal microbicides for preventing sexually transmitted hiv infection: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

100. Factors associated with antiretroviral treatment failure amongst people living with HIV on antiretroviral therapy in resource poor settings: a systematic review

Factors associated with antiretroviral treatment failure amongst people living with HIV on antiretroviral therapy in resource poor settings: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO